By Joan Faus
The net profit decline was steeper than the 29.9% registered in 2020. Core earnings before interest, taxes, depreciation, and amortisation (EBITDA) fell 16% in the first quarter to 74.2 million euros while total revenue reached 222.5 million euros, more than what was expected by analysts polled by Refinitiv.
The Barcelona-based pharmaceutical was hit by the pandemic as fewer patients went to the doctor as a result of the restrictions on mobility. The company’s sales also suffered from the introduction of generic competition in the United States.
It said on Monday it predicts COVID-19 will continue impacting its operations in the first half to “progressively normalize” in the second half of the year.
($1 = 0.8229 euros)
(Reporting by Joan Faus, Editing by Inti Landauro)